Ionis Pharmaceuticals Director Hayden Buys $1.1 Million Shares. What Does This Mean for Investors?
Insider holdings surged 34% through indirect acquisition, signaling confidence amid company's $8.8 billion valuation and RNA-therapy pipeline advancement.
Why it matters
Attributed market update with source link for portfolio context.